Advertisement
Screener

REPLIMUNE GROUP, INC. (REPL) Cash Flow Breakdown

REPLIMUNE GROUP, INC. Cash Flow Breakdown

Cash flow breakdown shows where REPLIMUNE GROUP, INC.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2026-03-31: from running the business, $280.34M went out.
  • Fiscal year ended 2026-03-31: from investing, $310.84M came in.
  • Fiscal year ended 2026-03-31: from financing, $66.29M came in.
  • Fiscal year ended 2026-03-31: change in cash, $97.91M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingDebt paid backNew debtNew shares soldNot split outChange in cash
2026-03-31-$280.34M$310.84M$35.00M$883.00K$30.41M*$97.91M
2025-03-31-$192.25M-$23.80M$0.00$155.73M$96.67M*$36.66M
2024-03-31-$185.47M$97.20M$15.00M$0.00$1.28M*-$72.07M
2023-03-31-$128.05M-$142.50M$28.15M$149.85M$133.29M*$40.64M
2022-03-31-$82.18M-$1.81M$0.00*$0.00$0.00$6.60M*-$76.57M
2021-03-31-$61.39M-$188.78M-$10.79M*$286.11M$97.15M*$123.02M
2020-03-31-$60.55M-$5.23M$10.00M$551.00K$89.61M*$34.25M
2019-03-31-$25.38M-$65.94M$206.00K$101.18M*$9.23M
2018-03-31-$16.01M-$44.05M$54.75M*-$3.01M
2017-03-31-$7.08M-$238.00K$15.00M*$6.27M

Each quarter (3 month)

Quarter endRunning the businessFrom investingDebt paid backNew debtNew shares soldNot split outChange in cash
2026-06-30-$75.73M$49.99M$1.00M-$23.66M
2026-03-31-$56.16M*$86.51M*$92.00K*$55.59M*
2025-12-31-$65.95M*$75.12M*$282.00K*$10.17M*
2025-09-30-$81.21M*$84.17M*$0.00*
2025-06-30-$77.02M$65.05M$0.00-$13.74M
2025-03-31-$53.73M*-$7.70M*$0.00*-$1.00K*
2024-12-31-$50.71M*-$46.32M*$107.53M*$48.41M*
2024-09-30-$38.64M*$458.00K*$0.00*
2024-06-30-$49.17M$29.77M$48.20M$48.43M*$77.20M
2024-03-31-$46.17M*$23.20M*$0.00*$0.00*
2023-12-31-$47.12M*$53.96M*$0.00*$14.87M*
2023-09-30-$43.59M*$12.68M*$0.00*
2023-06-30-$48.59M$7.36M$0.00$1.10M*-$40.11M
2023-03-31-$32.80M*-$22.75M*-$1.85M*-$248.00K*
2022-12-31-$28.59M*-$125.10M*$6.70M$264.74M*
2022-09-30-$33.21M*$36.00K*$6.70M$723.00K*
2022-06-30-$33.45M$5.32M$31.04M$1.49M*$6.30M
2022-03-31-$22.56M*-$4.33M*$0.00*$0.00*$0.00*
2021-12-31-$18.35M*-$13.42M*$0.00*$3.97M*
2021-09-30-$22.96M*-$11.05M*$0.00*$1.15M*
2021-06-30-$18.31M$26.99M$0.00$1.12M*$10.01M
2021-03-31-$16.13M*-$126.27M*$0.00*$0.00*$785.00K*
2020-12-31-$12.99M*$31.42M*$211.22M*$50.97M*
2020-09-30-$17.18M*-$44.80M*$291.00K*
2020-06-30-$15.09M-$49.13M$1.55M$107.97M*$45.30M
2020-03-31-$11.26M*$7.84M*$0.00*$71.00K*
2019-12-31-$15.73M*-$65.21M*$0.00*$357.00K*$90.01M*
2019-09-30-$19.97M*$25.32M*$105.00K*$9.64M*
2019-06-30-$13.58M$26.81M$18.00K$13.11M
2019-03-31-$6.03M*$10.47M*$41.00K*
2018-12-31-$6.10M*$3.80M*$153.00K*
2018-09-30-$6.38M*-$85.11M*$101.39M*$9.70M*
2018-06-30-$6.86M$4.89M-$2.90M
2018-03-31-$4.23M*-$18.08M*
2017-12-31-$2.69M*-$25.84M*
2017-09-30-$3.59M*-$101.00K*$51.65M*
2017-06-30-$5.49M-$33.00K-$4.63M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vor Biopharma Inc. (VOR)United States$1.091B1.60
MeiraGTx Holdings plc (MGTX)United States$1.061B16.10
Monte Rosa Therapeutics, Inc. (GLUE)United States$1.002B-12.81
Cullinan Therapeutics, Inc. (CGEM)United States$0.993B-5.72
Odyssey Therapeutics, Inc. (ODTX)United States$0.960B
Maze Therapeutics, Inc. (MAZE)United States$1.457B-12.40
Inhibrx Biosciences, Inc. (INBX)United States$1.477B-10.08
Sana Biotechnology, Inc. (SANA)United States$0.886B-4.92
Candel Therapeutics, Inc. (CADL)United States$0.885B-8.86
Attovia Therapeutics, Inc. (ATTO)United States$0.828B